Chennai Meenakshi Multispeciality Hospital Ltd vs Dr Lalchandani Labs Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Oct 25, 2026

Key Highlights

The Latest Trading Price of Chennai Meenakshi Multispeciality Hospital Ltd is ₹ 36.4 as of 23 Oct 15:30 . The P/E Ratio of Chennai Meenakshi Multispeciality Hospital Ltd changed from 4.3 on March 2022 to 0 on March 2026 . This represents a CAGR of -100.00% over 5 yearsThe P/E Ratio of Dr Lalchandani Labs Ltd changed from 6 on March 2021 to 0 on March 2026 . This represents a CAGR of -100.00% over 6 years The Market Cap of Chennai Meenakshi Multispeciality Hospital Ltd changed from ₹ 7.28 crore on March 2021 to ₹ 24.66 crore on March 2026 . This represents a CAGR of 22.55% over 6 yearsThe Market Cap of Dr Lalchandani Labs Ltd changed from ₹ 6.02 crore on March 2021 to ₹ 0 crore on March 2026 . This represents a CAGR of -100.00% over 6 years The revenue of Chennai Meenakshi Multispeciality Hospital Ltd for the Jun '26 is ₹ 8.7 crore as compare to the Mar '26 revenue of ₹ 10.05 crore. This represent the decline of -13.43% The revenue of Dr Lalchandani Labs Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Chennai Meenakshi Multispeciality Hospital Ltd for the Jun '26 is ₹ 0.46 crore as compare to the Mar '26 ebitda of ₹ 0.48 crore. This represent the decline of -4.17% The ebitda of Dr Lalchandani Labs Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Chennai Meenakshi Multispeciality Hospital Ltd changed from ₹ -0.38 crore to ₹ 0 crore over 9 quarters. This represents a CAGR of -100.00% The net profit of Dr Lalchandani Labs Ltd changed from ₹ 0 crore to ₹ 0 crore over 9 quarters. This represents a CAGR of 0.0% The Dividend Payout of Chennai Meenakshi Multispeciality Hospital Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Dividend Payout of Dr Lalchandani Labs Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 years .

About Chennai Meenakshi Multispeciality Hospital Ltd

Chennai Meenakshi Multispeciality Hospital Limited, formerly known as Devaki Hospital Limited, was incorporated in 1990.
The Company name was changed from Devaki Hospital Limited to Chennai Meenakshi Multispeciality Hospital Limited in October, 2007.
It is a 100-bedded hospital located in the heart of Chennai at Mylapore.
The hospital has an infrastructure comprising of around 105 Beds including ICU Beds, Operating Theatre, a modern dialysis Unit besides a host of other facilities.
The Company has a pool of talented and experienced doctors who are further supported by a team of highly qualified and experienced and dedicated support staff and cutting edge technology. The Company operate into various departments like Cardiology Department; Casualty Department; Diagnostic Services; Intensive Care Unit; Nephrology Department and Physiotherapy Department.

About Dr Lalchandani Labs Ltd

Dr Lalchandani Labs Limited was originally incorporated as Partnership Firm at New Delhi dated 15 September, 2011 in the name of Dr. A Lalchandani Pathology Laboratories.
Thereafter, the Partnership Firm was taken over by M/s Dr Lalchandani Labs Limited on 2nd August, 2017 issued by the Registrar of Companies, Delhi vide agreement dated 31st August, 2017.
The Firm was established by Dr. Arjan Lal Chandani and his son Mr. Mohit Lal Chandani as a Partnership Firm in the name of 'Dr. A Lalchandani Pathology Laboratories' in 2011 and in year 2017, they formed a Company in the name and style M/s Dr Lalchandani Labs Limited and took over the Partnership firm. The Company is a provider of diagnostic and related healthcare tests and services in Delhi/NCR. Through its integrated network, it offers patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.

FAQs for the comparison of Chennai Meenakshi Multispeciality Hospital Ltd and Dr Lalchandani Labs Ltd

Which company has a larger market capitalization, Chennai Meenakshi Multispeciality Hospital Ltd or Dr Lalchandani Labs Ltd?

Market cap of Chennai Meenakshi Multispeciality Hospital Ltd is 27 Cr while Market cap of Dr Lalchandani Labs Ltd is 6 Cr

What are the key factors driving the stock performance of Chennai Meenakshi Multispeciality Hospital Ltd and Dr Lalchandani Labs Ltd?

The stock performance of Chennai Meenakshi Multispeciality Hospital Ltd and Dr Lalchandani Labs Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Chennai Meenakshi Multispeciality Hospital Ltd and Dr Lalchandani Labs Ltd?

As of October 25, 2026, the Chennai Meenakshi Multispeciality Hospital Ltd stock price is INR ₹36.4. On the other hand, Dr Lalchandani Labs Ltd stock price is INR ₹6.96.

How do dividend payouts of Chennai Meenakshi Multispeciality Hospital Ltd and Dr Lalchandani Labs Ltd compare?

To compare the dividend payouts of Chennai Meenakshi Multispeciality Hospital Ltd and Dr Lalchandani Labs Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.